Abstract:PARP inhibitors have been an effective treatment option for cancers deficient in homologous recombination repair, such as ovarian, breast, prostate, and pancreatic cancers, particularly those harboring BRCA mutations. However, their severe overlapping hematological and gastrointestinal toxicities have limited their clinical use, especially in the combination therapies with other anti-cancer agents. More recently, studies have shown that inhibiting PARP1 mainly drives anti-tumor activity while inhibiting PARP2 contributes to the hematological toxicity such as anemia due to its essential role in the survival of hematopoietic stem and progenitor cells. Thus, there is an urgent need for developing a selective PARP1 inhibitor. In this study, we report the discovery and characterization of a unique PARP1 inhibitor, ACE-86225106. This molecule is highly selective at inhibiting PARP1 over PARP2 as demonstrated in biochemical (72x) and DNA-trapping (131x) assays. It demonstrates potent anti-proliferative activities against BRCA mutant cancer cell lines (IC50 = 1-9 nM) but not against BRCA wild type cancer cells (IC50 >30,000 nM). As compared to the BRCA mutant cancer cells, this molecule is much less active at inhibiting the differentiation of CD34+ hematopoietic stem cells (IC50 ≈ 450-1,400 nM), i.e.: erythroid, myeloid and megakaryocyte. The results of these studies show that ACE-86225106 is a highly potent and selective PARP1 inhibitor. This molecule has a unique PK profile characterized by its long half-life and low volume of distribution. As such, it demonstrates robust efficacy at low dose (1 mg/kg) with a less frequent dosing schedule (once a week). Importantly, there was no significant body weight loss observed in the treatment group even at much higher doses (10 mg/kg), but there was a significant body weight gain. The GLP toxicology studies have confirmed its superior safety profile as the maximum recommended safe starting first-in-human dose was >5-fold higher than the predicted human efficacious dose. Taken together, ACE-86225106 is a highly potent, selective PARP1 inhibitor with excellent PK and safety profile and expected to have a better safety profile, deeper and more durable clinical responses, and broader utility in the clinic as a preferred combination partner with other anti-cancer therapies. A phase 1 clinical trial to evaluate its safety, PK, and clinical utility is to begin in early 2024. Citation Format: Yi Wei, Wenming Li, Zehui Li, Manhua Li, Kai Kang, Zhiming Wen, Tinggui Yin, Kuo-Long Yu, Genshi Zhao, Hongbin Yuan. Discovery of a highly potent and selective PARP1 inhibitor with superior PK and safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4525.

Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability

Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors.

Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Discovery of highly potent PARP7 inhibitors for cancer immunotherapy

Abstract 1834: Discovery of a novel and highly selective PARP7 inhibitor for cancer immunotherapy

Abstract 4535: JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity

Synthesis and in Vitro Biological Evaluation of 3-Ethyl-1,5-naphthyridin-2(1h)-one Derivatives As Potent PARP-1 Selective Inhibitors and PARP-1 DNA Trappers

Discovery of Novel Benzamide Derivatives Bearing Benzamidophenyl and Phenylacetamidophenyl Scaffolds As Potential Antitumor Agents Via Targeting PARP-1.

Abstract 7588: Discovery of NSP-5033: A novel and potent PARP7/12 dual inhibitor

Discovery of Novel Bromophenol Thiosemicarbazone Hybrids As Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors As a Promising Strategy for Cancer Therapy

Novel Tricyclic Poly (Adp-Ribose) Polymerase-1/2 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis and Biological Evaluation.

Discovery of Pyrazolo[1,5,4-de]quinoxalin-2(3H)-one Derivatives as Highly Potent and Selective PARP1 Inhibitors.

Discovery of Novel PARP/PI3K Dual Inhibitors with High Efficiency Against BRCA-proficient Triple Negative Breast Cancer.

Discovery, Mechanism and Metabolism Studies of 2,3-Difluorophenyl-linker-containing PARP1 Inhibitors with Enhanced in Vivo Efficacy for Cancer Therapy

Discovery of Novel PARP1/NRP1 Dual-Targeting Inhibitors with Strong Antitumor Potency

Abstract 4525: Discovery of a highly potent and selective PARP1 inhibitor with superior PK and safety profiles

Discovery of Novel and Potent PARP/PI3K Dual Inhibitors for the Treatment of Cancer

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Identification of Novel PARP-1 Inhibitors: Drug Design, Synthesis and Biological Evaluation.

Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis